Amicus Therapeutics reported third-quarter 2025 revenue of $169.1 million, up 17% at constant exchange rates, and delivered GAAP net income of $17.3 million, marking a pivot to profitability on the strength of two rare-disease franchises. Galafold contributed $138.3 million, up 12% at constant exchange rates, while Pombiliti + Opfolda rose 42% at constant exchange rates to $30.7 million. Cash and marketable securities increased to $263.8 million. The company reiterated 2025 guidance, highlighted recent pricing and reimbursement wins including Japan and Belgium, secured EMA approval for WuXi Biologics’ Dundalk, Ireland site as a commercial manufacturing facility for Pombiliti, and maintained timelines for full enrollment of the Phase 3 ACTION3 trial of DMX-200 in FSGS by year-end.
The strategic signal is clear: Amicus is attempting to convert a focused rare-disease portfolio into durable, double-digit growth while de-risking supply and widening market access. The core question is whether momentum is structural or transient. Galafold’s trajectory depends on continued identification of amenable Fabry patients and persistence on therapy, while Pombiliti + Opfolda must carve share against entrenched enzyme replacement therapies and next-generation competitors. With roughly $4 million of currency tailwind this quarter, underlying demand remains the primary driver, but sustaining that demand will hinge on evidence and execution more than macro factors.
For patients and HCPs, the near-term impact is expanded access and potential continuity of care. Completed pricing and reimbursement agreements in additional geographies, including Japan, should accelerate initiation for late-onset Pompe patients not improving on current therapy, and expanding Galafold adoption depends on genotype-driven identification and streamlined diagnostic pathways. New four-year open-label extension data for Pombiliti + Opfolda, showing stability or improvement across functional measures and biomarkers in ERT-experienced patients, can underpin treatment confidence and support payer renewals. Medical Affairs teams will need to translate these data into practical guidance for clinic workflows, while building real-world evidence that resonates with HTA bodies focused on long-term functional outcomes and resource utilization.
Commercial dynamics are sharpening. In Fabry, the shift from infusion-center ERT to an oral chaperone model is attractive for adherence and system costs, but payers will scrutinize durable organ outcomes and the size of the amenable population. In Pompe, differentiation against newer ERTs will hinge on meaningful functional benefits and manageable infusion burden. On the operations front, EMA authorization of WuXi’s Ireland facility adds geographic redundancy within the contract manufacturing network, aligning with an industry-wide push to diversify supply chains, anticipate regulatory inspections, and mitigate geopolitical risk. This matters as Amicus pursues up to 10 new launch countries in 2025 where supply reliability, lot release timeliness, and pharmacovigilance readiness can determine the slope of uptake.
The longer arc centers on portfolio breadth. Management’s ambition to surpass $1 billion in sales by 2028 likely requires Pombiliti + Opfolda to scale materially and a third revenue pillar to emerge. DMX-200 in FSGS, a high-need nephrology indication with no approved therapies, offers that optionality if Phase 3 reads out positively and if Amicus can translate nephrology engagement and payer education into swift access. The next strategic choice is whether to double down on lysosomal and nephrology adjacencies through business development or concentrate resources on deepening label and line-of-therapy expansion for the current assets. For commercial and medical leaders watching the sector, the test is whether Amicus can convert early profitability into platform durability—or whether it must pursue bolder in-licensing to avoid a growth plateau.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
